Health Care • Medical Specialities
$38.51 ▲ +1.83
(+4.99%)
MKT CAP: $1.18B • VOL: 723.9K
52W L $18 52W H $44
CSTL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $344.2M | $332.1M | $219.8M |
| YoY Revenue Growth % | +3.7% | +51.1% | — |
| Gross Profit | $273.2M | $271.9M | — |
| Gross Margin % | 79.4% | 81.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.8M | $8.7M | -$68.0M |
| Operating Margin % | -12.4% | 2.6% | -30.9% |
| Net Income (GAAP) | -$24.2M | $18.2M | -$57.5M |
| EBITDA (Normalized) | -$14.0M | $31.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $64.3M | $64.9M | -$5.6M |
| Capital Expenditures (CapEx) | $36.0M | $28.3M | — |
| Free Cash Flow (FCF) | $28.3M | $36.5M | -$5.6M |
| FCF Margin % | 8.2% | 11.0% | -2.6% |
| Return on Invested Capital (ROIC %) | -9.3% | 2.0% | — |
| Cash & Short-Term Equivalents | $116.7M | $119.7M | — |
| Total Debt (Short + Long Term) | $9.6M | $9.7M | — |
| Total Stockholders' Equity | $470.9M | $455.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CSTL.